Abstract LB178: Cell free RNA for prediction of PDAC in de novo symptomatic patients presenting for EUS-FNA

Abstract Endoscopic ultrasound (EUS), the primary procedure for the diagnosis of pancreatic ductal adenocarcinoma (PDAC), the most lethal cancer, is invasive. We aim to develop a liquid biopsy approach using plasma cell-free messenger RNA to stratify patients prior to EUS and assist in the precision diagnosis of PDAC. We found a set of plasma cell-free messenger RNA biomarkers and a set of robust reference genes to classify PDAC patients from intermediary pancreatic pathologies such as: benign cases, pancreatitis, and intraductal papillary mucinous neoplasm (IPMN) with reproducible results validated in separate cohorts. Our results demonstrate a non-invasive liquid biopsy approach for stratifying patient groups before invasive and definitive EUS screening. Citation Format: Travis Moore, Elias Spiliotopolous, Rowan Callahan, Ward Kirschbaum, Hyun Ji Kim, Dove Keith, Aaron Grossberg, Paul T. Spellman, Gordon Mills, Rosalie C. Sears, Terry Morgan, Thuy Ngo. Cell free RNA for prediction of PDAC in de novo symptomatic patients presenting for EUS-FNA [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB178.